Optimal Management of Hypertension in Patients with Stroke Risk and Hyperlipidemia

Primary Recommendation: RAS Inhibition

The American Heart Association recommends starting with an ACE inhibitor (such as lisinopril 10 mg daily) or an angiotensin receptor blocker (ARB, such as losartan 50 mg daily) as first-line therapy for patients under 55 years of age with hypertension, due to their excellent safety profile and superior stroke risk reduction compared to other antihypertensive classes 1, 2
RAS inhibitors provide comprehensive cardiovascular protection in patients with hyperlipidemia and multiple risk factors, addressing both blood pressure control and vascular protection 1
The International Society of Hypertension specifically recommends RAS inhibitors and diuretics for patients with psychiatric diseases due to their lower rate of pharmacological interactions with antidepressants 1

Start with lisinopril 10 mg daily or losartan 50 mg daily as monotherapy, and monitor blood pressure, renal function, and potassium at 1-2 weeks after initiation 1, 3, 4
Target blood pressure is <130/80 mmHg, with a minimum acceptable target of <140/90 mmHg 1, 4
If uncontrolled after 4-6 weeks, increase to maximum dose: lisinopril 40 mg daily or losartan 100 mg daily, and recheck blood pressure, creatinine, and potassium 1-2 weeks after dose titration 3, 4

Avoid beta-blockers as first-line therapy in patients unless they develop tachycardia from quetiapine or have another specific indication (coronary disease, heart failure) 1, 5
Alpha-1 blockers (doxazosin) should be used with caution in patients on SSRIs due to increased orthostatic hypotension risk 1

Continue atorvastatin and ensure adequate dosing for primary prevention given the patient's age, hypertension, and family history of early stroke 1, 2
Target LDL-C <100 mg/dL (2.6 mmol/L) for primary prevention in high-risk patients 1

Check blood pressure, creatinine, and potassium at 1-2 weeks after any medication initiation or dose change, and achieve target blood pressure control within 3 months 3, 4
Aim for at least a 20/10 mmHg reduction from baseline with an ideal target of <130/80 mmHg 3, 4
Once blood pressure is controlled and stable, monitor every 4-6 months for patients on ACE inhibitors/ARBs, and continue monitoring renal function and electrolytes at each visit 4